Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care
Firefly Neuroscience partners with NeuroSigma to expand access to the FDA-cleared Monarch eTNS non-drug ADHD treatment nationwide.
Stocks · News reference
Firefly Neuroscience Partners With NeuroSigma To Expand Clinician Awareness Of And Access To The Monarch eTNS System
Collaboration to use Firefly’s growing nationwide network of Evoke™ clinician customers. The Monarch eTNS® System is the first non-drug treatment for pediatric attention-deficit/hyperactivity disorder ("ADHD")
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Firefly Neuroscience shares are trading higher after the company announced a partnership with NeuroSigma to expand access to the Monarch eTNS System through its Evoke clinician network.
Why Alaunos Therapeutics Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Alaunos rose 21.8% after adopting amended bylaws; Cheetah Net led gainers, while Xenon dropped 27.6% after pausing study enrollment.